Health Care [ 3/12 ] | Pharmaceuticals [ 37/74 ]
NASDAQ | Common Stock
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.
The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases.
It has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy.
Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 5, 24 | -0.46 Decreased by -18.79% | -0.41 Decreased by -13.00% |
| Jul 31, 24 | 0.87 Increased by +328.95% | -0.01 Increased by +8.80 K% |
| May 13, 24 | -0.43 Decreased by -4.88% | -0.44 Increased by +2.27% |
| Feb 27, 24 | -0.40 Increased by +20.00% | -0.43 Increased by +6.98% |
| Nov 7, 23 | -0.39 Increased by +23.53% | -0.43 Increased by +9.30% |
| Aug 3, 23 | -0.38 Increased by +54.22% | -0.44 Increased by +13.64% |
| May 15, 23 | -0.41 Increased by +35.94% | -0.46 Increased by +10.87% |
| Mar 9, 23 | -0.50 Increased by +13.79% | -0.49 Decreased by -2.04% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 0.00 Decreased by -100.00% | -21.70 M Increased by +9.66% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 80.00 M Increased by +8.99 K% | 55.41 M Increased by +332.98% | Increased by +69.26% Increased by +102.56% |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -26.87 M Decreased by -24.29% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 871.00 K Increased by +27.15% | -24.76 M Decreased by -4.77% | Decreased by -2.84 K% Increased by +17.61% |
| Sep 30, 23 | 759.00 K Decreased by -35.84% | -24.02 M Increased by +0.14% | Decreased by -3.16 K% Decreased by -55.64% |
| Jun 30, 23 | 880.00 K Decreased by -53.24% | -23.78 M Increased by +29.85% | Decreased by -2.70 K% Decreased by -50.02% |
| Mar 31, 23 | 295.00 K Decreased by -88.62% | -21.62 M Increased by +16.40% | Decreased by -7.33 K% Decreased by -634.57% |
| Dec 31, 22 | 685.00 K Decreased by -86.46% | -23.63 M Decreased by -0.62% | Decreased by -3.45 K% Decreased by -642.98% |